ChanTest Launches Redesigned Web Site

Monday, June 9, 2008 General News J E 4
CLEVELAND, June 9 ChanTest, the leading provider of ionchannel testing services for drug-discovery and development applications, haslaunched a completely redesigned Web site at

According to Dr. Arthur Brown, founder and CEO of ChanTest, the company'sgoal was to make the site more accessible to visitors, while providingsignificant improvements in content, navigation, and visual appeal. "TheInternet is an important part of our strategy to meet the needs of the drugdiscovery and development community," said Dr. Brown. "For example, our 'Ask aScientist' feature makes it easy, at a click of a button, to consult aChanTest ion channel expert. We also take seriously our commitment to be aresource for members of the press and others who may be interested in learningmore about the importance of ion channels in drug safety. An explanation ofthe cardiac safety issue can be found under 'Technology & Applications' fromthe main menu."

The new design structure makes it easier for users to find Web content.For example, many of the more than 300 articles by ChanTest scientists thathave appeared in peer-reviewed journals can be downloaded easily by clickingon the article title. This comprehensive list of ChanTest articles can befound on the "Publications" page, accessible from "Technology & Applications"on the main menu. The site also features an extensive search function,scrolling headlines highlighting what's new, and listings of upcomingconferences and events.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drugdiscovery and development customers with GLP safety and automated screeningassays using its library of ion channel-expressing cell lines - the mostcomprehensive in the world. Since its inception in 1998, ChanTest has testedmore than 12,000 compounds for more than 250 global pharmaceutical and biotechcompanies - helping them to achieve their drug safety and discovery goals.ChanTest works in partnership with customers to speed the drug-developmentprocess, save time and money, and ultimately - to help make better, saferdrugs. Because of ChanTest's seminal role in this field, along with thecompany's uncompromising commitment to quality, ChanTest was named "mosttrusted fee-for-service provider" for ion channel screening in the HTStec IonChannel Trends Survey for two years in a row. ChanTest is based in Cleveland,Ohio. For more information, please visit



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Memory Pharmaceuticals Receives Anticipated NASDAQ...
Microsoft and Kaiser Permanente to Hold Joint Conf...